HK1211036A1 - Recombinant cell surface capture proteins - Google Patents

Recombinant cell surface capture proteins

Info

Publication number
HK1211036A1
HK1211036A1 HK15111643.1A HK15111643A HK1211036A1 HK 1211036 A1 HK1211036 A1 HK 1211036A1 HK 15111643 A HK15111643 A HK 15111643A HK 1211036 A1 HK1211036 A1 HK 1211036A1
Authority
HK
Hong Kong
Prior art keywords
cell surface
recombinant cell
surface capture
capture proteins
proteins
Prior art date
Application number
HK15111643.1A
Other languages
English (en)
Chinese (zh)
Inventor
‧德施潘德
陳剛
‧布拉科夫
‧凡德爾
‧奧爾德里奇
‧卡馬特
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1211036A1 publication Critical patent/HK1211036A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
HK15111643.1A 2012-11-14 2015-11-26 Recombinant cell surface capture proteins HK1211036A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726040P 2012-11-14 2012-11-14
PCT/US2013/069993 WO2014078475A2 (en) 2012-11-14 2013-11-14 Recombinant cell surface capture proteins

Publications (1)

Publication Number Publication Date
HK1211036A1 true HK1211036A1 (en) 2016-05-13

Family

ID=49679651

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111643.1A HK1211036A1 (en) 2012-11-14 2015-11-26 Recombinant cell surface capture proteins
HK16102584.0A HK1214612A1 (zh) 2012-11-14 2016-03-07 重組的細胞表面捕捉蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102584.0A HK1214612A1 (zh) 2012-11-14 2016-03-07 重組的細胞表面捕捉蛋白

Country Status (20)

Country Link
US (3) US9758592B2 (ko)
EP (2) EP2920208B1 (ko)
JP (2) JP6668074B2 (ko)
KR (4) KR102563030B1 (ko)
CN (2) CN109485728A (ko)
AR (2) AR093491A1 (ko)
AU (3) AU2013344769B2 (ko)
BR (1) BR112015010758A2 (ko)
CA (2) CA2889541C (ko)
DK (2) DK2920208T3 (ko)
EA (2) EA202190266A1 (ko)
ES (2) ES2817373T3 (ko)
HK (2) HK1211036A1 (ko)
IL (3) IL238176B (ko)
MX (2) MX2015006112A (ko)
PL (2) PL2920208T3 (ko)
SG (2) SG10201804124XA (ko)
TW (3) TW202206465A (ko)
WO (1) WO2014078475A2 (ko)
ZA (1) ZA201502538B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
PT2888283T (pt) 2012-08-24 2018-11-16 Univ California Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
BR112017010555A2 (pt) 2014-11-20 2018-02-27 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd composições e métodos para produção de polipeptídeos com padrão de glicosilação modificado em células vegetais
PL3294775T3 (pl) * 2015-05-12 2021-12-13 Regeneron Pharmaceuticals, Inc. Oznaczanie czystości białka multimerycznego
US10633445B2 (en) 2015-09-15 2020-04-28 Board Of Regents The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
JP7134868B2 (ja) 2016-04-20 2022-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 発現強化座位の使用に基づく抗体を作製するための組成物および方法
TWI827531B (zh) 2016-04-20 2024-01-01 美商再生元醫藥公司 基於使用增強表現基因座之製備抗體的組成物及方法
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
IL312457A (en) * 2017-03-24 2024-06-01 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane trapping of monoclonal immunoglobulins secreted by hybridomas
CN107177613A (zh) * 2017-07-18 2017-09-19 哈尔滨紫霞生物科技有限公司 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法
EP3720884A4 (en) * 2017-12-07 2021-09-29 Chugai Seiyaku Kabushiki Kaisha ANTIBODIES, COMPOSITIONS FOR USE IN THE DETECTION OR DETERMINATION OF A POLYPEPTIDE IN A SAMPLE, AND METHODS OF DETECTING OR DETERMINING A POLYPEPTIDE IN A SAMPLE
EP3856910A4 (en) * 2018-09-24 2022-09-28 Merck Sharp & Dohme Corp. EXPRESSION VECTORS FOR EUKARYOT EXPRESSION SYSTEMS
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CN114874333A (zh) * 2021-10-18 2022-08-09 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151350A (en) 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
US5635354A (en) 1991-01-09 1997-06-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
EP1324040A3 (en) 1992-10-21 2007-06-20 MILTENYI, Stefan Direct selection of cells by secretion product
US6482655B1 (en) 1993-07-23 2002-11-19 University Of Utah Research Foundation Immunoassay procedure utilizing fluorogenic tracer antigens
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CN101712720A (zh) 1996-02-09 2010-05-26 艾博特生物技术有限公司 结合人TNFα的人抗体
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
CA2330678C (en) 1998-05-11 2009-04-07 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific t cells
CA2331917A1 (en) 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Novel method for gene cloning
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
ES2239246T3 (es) 2001-08-31 2005-09-16 Avidex Limited Receptor soluble de celulas t.
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
RU2007145509A (ru) * 2005-05-09 2009-06-20 Гликарт Биотехнологи Аг (Ch) Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами
PL2178916T3 (pl) * 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
RU2522002C2 (ru) * 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
ES2777901T3 (es) 2009-12-25 2020-08-06 Chugai Pharmaceutical Co Ltd Método de modificación de polipéptidos para purificar multímeros polipeptídicos
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質

Also Published As

Publication number Publication date
US9758592B2 (en) 2017-09-12
HK1214612A1 (zh) 2016-07-29
DK2949667T3 (da) 2020-07-20
DK2920208T3 (da) 2020-09-14
TW201920289A (zh) 2019-06-01
ES2817373T3 (es) 2021-04-07
PL2920208T3 (pl) 2021-02-08
MX2015006112A (es) 2015-08-06
US20140134719A1 (en) 2014-05-15
JP6856593B2 (ja) 2021-04-07
WO2014078475A2 (en) 2014-05-22
KR102563030B1 (ko) 2023-08-03
JP6668074B2 (ja) 2020-03-18
US20180118852A1 (en) 2018-05-03
KR20210014766A (ko) 2021-02-09
ZA201502538B (en) 2017-09-27
IL285015A (en) 2021-08-31
CN109485728A (zh) 2019-03-19
SG10201804124XA (en) 2018-07-30
IL275270B (en) 2021-08-31
AU2018253474B2 (en) 2021-01-21
EP2920208B1 (en) 2020-08-19
PL2949667T3 (pl) 2020-11-16
KR20220025902A (ko) 2022-03-03
EA202190266A1 (ru) 2021-07-30
IL275270A (en) 2020-07-30
EP2920208A2 (en) 2015-09-23
AR121002A2 (es) 2022-04-06
EA037546B1 (ru) 2021-04-12
JP2019023199A (ja) 2019-02-14
IL238176B (en) 2020-06-30
BR112015010758A2 (pt) 2017-08-22
TW202206465A (zh) 2022-02-16
JP2015536345A (ja) 2015-12-21
CN104797598B (zh) 2018-12-11
ES2805526T3 (es) 2021-02-12
TWI745610B (zh) 2021-11-11
AU2013344769B2 (en) 2018-11-15
WO2014078475A3 (en) 2014-11-20
KR20230119245A (ko) 2023-08-16
AR093491A1 (es) 2015-06-10
CN104797598A (zh) 2015-07-22
EP2949667A3 (en) 2016-02-24
AU2021202371A1 (en) 2021-05-13
AU2013344769A1 (en) 2015-05-21
KR20150084028A (ko) 2015-07-21
EP2949667A2 (en) 2015-12-02
AU2018253474A1 (en) 2018-11-15
EA201590928A1 (ru) 2015-09-30
MX2019015887A (es) 2020-02-07
CA3204343A1 (en) 2014-05-22
CA2889541C (en) 2023-07-04
IL238176A0 (en) 2015-05-31
US20210009714A1 (en) 2021-01-14
EP2949667B1 (en) 2020-05-13
TWI675044B (zh) 2019-10-21
TW201439121A (zh) 2014-10-16
SG11201502629TA (en) 2015-05-28
CA2889541A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
IL285015A (en) Recombinant cell surface capture proteins
HRP20190454T1 (hr) Rekombinantni faktor viii proteini
IL291571A (en) cx3cr1 binding polypeptides
HK1209651A1 (en) Cells for producing recombinant iduronate-2-sulfatase -2-
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
GB201220474D0 (en) Polypeptides
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
PL2714888T3 (pl) Rekombinowane drożdże
SG11201404180RA (en) Cho-gmt recombinant protein expression
GB201200555D0 (en) Peptide
GB201220899D0 (en) CD44v6-derived pegylated peptides
GB201223114D0 (en) Novel peptide
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
HK1211952A1 (en) Recombinant protein
GB201210286D0 (en) Recombinant polypeptide
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
GB201203941D0 (en) Polypeptide detection
GB201204065D0 (en) Fusion polypeptide
GB201103967D0 (en) Polypeptide detection
GB201221414D0 (en) Trans-locating peptide
GB201200623D0 (en) Peptide
GB201200624D0 (en) Peptide
GB201200509D0 (en) Peptides